The APOLLO trial, as the first phase II clinical study to evaluate the efficacy of almonertinib in the second-line treatment, found that the ORR of almonertinib in NSCLC with EGFR T790M resistant mutation was 68.9% (95% CI: 62.6-74.6), and the DCR was 93.4% (95% CI: 89.6-96.2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.